glp-1 masld Direct and indirect effects of GLP1‐RA in obesity, T2D and Systemic evaluation of the effects

doi: 10.1016/S2213-8587(19)30180-9 10 MarsoSPDanielsGHBrown-FrandsenKKristensenPMannJFNauckMAet al

The most common side effects are stomach-related: nausea, diarrhea, vomiting, and constipation, especially during dose escalation

In addition to their established benefits for the management of diabetes and obesity, GLP-1RAs have shown potential in managing MASLD through mechanisms such as reducing hepatic lipogenesis, improving insulin sensitivity, and modulating inflammation

For example, liraglutide, though also effective, typically results in somewhat lower overall weight loss than semaglutide, with dulaglutide and exenatide demonstrating similarly modest outcomes by comparison

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes

Output: Volume to draw up (ml and IU)